ArticleJournal of ovarian research2026
Integrative metabolomics and proteomics reveal early cardiovascular risk signatures in PCOS female offspring.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPolycystic ovary syndrome (PCOS) is associated with metabolism abnormalities and increased cardiovascular disease (CVD) risk. This study aimed to further investigate cardiovascular metabolism alterations specifically in the female offspring of PCOS patients using metabolomics and proteomics, and to identify potential early CVD-related biomarkers in this population.
methodsA total of 40 female offspring of PCOS patients and 40 female offspring of non-PCOS individuals (4–6 years old) were enrolled in this study. Cardiovascular risk features including height, weight, body mass index (BMI), blood pressure, glycemic and lipid parameters were assessed. Untargeted metabolomics and the Olink proteomics were applied to identify alterations in metabolites and CVD-related proteins. A further in-depth analysis of metabolomics and proteomics was conducted.
resultsLipid indicators, including Total Cholesterol（TC）, Low-Density Lipoprotein Cholesterol（LDL-C）, and high-density lipoprotein cholesterol (HDL-C), as well as γ-glutamyl transferase (GGT), a marker of liver function were significantly elevated in the female offspring of PCOS patients compared to the female offspring of non-PCOS women. Metabolomic profiling revealed significant alterations in lipid metabolites, particularly in glycerophospholipids and fatty acids, in the female offspring of PCOS patients. Additionally, elevated levels of CVD-related proteins, including proprotein convertase subtilisin/kexin type (PCSK9), tissue factor pathway inhibitor (TFPI), secretoglobin family 3A member 2 (SCGB3A2), junctional adhesion molecule A (JAM-A), interleukin-1 receptor-like 1 (ST2) and epidermal growth factor receptor (EGFR) were observed, with significant correlations between these proteins and the altered lipid metabolites. We conducted mediation analysis and identified several metabolites and proteins that mediate cardiovascular risk. A a combined metabolite and protein panel consisting of phospholipids (PIs), lysophosphatidylcholines (LysoPCs), and CVD-related proteins demonstrated an area under the curve (AUC) of 0.93 based on receiver operating characteristic (ROC) curve analysis, effectively differentiating female offspring with hyperlipidemia.
conclusionsFemale offspring of PCOS patients exhibit distinct lipid metabolic and protein profiles that suggest early cardiovascular-related alterations. These findings support the potential value of early metabolic monitoring in this population and highlight the need for longitudinal studies to determine whether these alterations translate to increased cardiovascular risk in adulthood. The identified metabolite and protein biomarkers may serve as tools for early risk assessment, pending prospective validation of their long-term predictive value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.